Drugs / PG2
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01325233 | Mar 2011 → Sep 2013 | hemorrhagic stroke | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01696565 | Dec 2001 → Oct 2003 | metastatic neoplasm, neoplasm | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05440227 | May 2023 → Dec 2025 overdue | — | PhytoHealth Corporation | Recruiting | No outcome recorded |
| Phase 2 | NCT02077621 | Feb 2014 → Dec 2020 | cancer | PhytoHealth Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT01603667 | Jun 2012 → Oct 2015 | cerebrovascular disorder | China Medical University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00860600 | Sep 2008 → Aug 2011 | autoimmune thrombocytopenic purpura | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00518869 | Sep 2007 → Jun 2008 | — | PhytoHealth Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT00523107 | Aug 2007 → Jan 2008 | — | PhytoHealth Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01603667 ↗ |
| Known as | PG2 injection 500mg | “PG2 injection 500mg” NCT02077621 ↗ |
| Route | Intravenous | “500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for...” NCT00518869 ↗ |